Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.
about
A systematic evaluation of laboratory testing for drug-induced immune thrombocytopeniaTreatment of drug-induced thrombocytopenia.Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.Profound thrombocytopenia after primary exposure to eptifibatide.Thrombocytopenia in the intensive care unit.Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.The drug-target residence time model: a 10-year retrospective.Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa aA Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion.
P2860
Q27686838-B4EA206D-9B95-45F0-9F9B-EC96BFFEA689Q33349372-ADB4D6AE-0BC3-4141-B5C3-0A6BCD19ABE2Q33370200-66C02310-2E5F-4239-9D12-A8178AEC6D44Q33388452-45D85447-2555-4C60-AA4C-C79B0B97A826Q33395925-DE5E7ACF-9186-4B05-87F7-C2863991ED93Q33399094-A259F72A-8BCC-4D23-9622-CC777D181EE6Q33400668-A2818304-C3C2-4D2C-A722-2FD8E17D756CQ33401497-2B47A97E-5469-4A0D-89F1-8BD11ED8E321Q33402176-33E9ED11-F76B-43C9-89A3-60C58B176DA6Q38672210-EDCDD24A-DAE5-439C-AD98-E833AA4A5C3CQ44506548-D3A2E0F3-FD41-4551-BD90-7002570AFC65Q55442994-E5B600DF-F344-4CFD-9555-C8D2AEE619DC
P2860
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Evidence that thrombocytopenia ...... ntagonists is immune mediated.
@ast
Evidence that thrombocytopenia ...... ntagonists is immune mediated.
@en
type
label
Evidence that thrombocytopenia ...... ntagonists is immune mediated.
@ast
Evidence that thrombocytopenia ...... ntagonists is immune mediated.
@en
prefLabel
Evidence that thrombocytopenia ...... ntagonists is immune mediated.
@ast
Evidence that thrombocytopenia ...... ntagonists is immune mediated.
@en
P2093
P1433
P1476
Evidence that thrombocytopenia ...... ntagonists is immune mediated.
@en
P2093
Beth E Thomas
Cathy J Kieras
Debra A Cromley
Dietmar Seiffert
Donna L Pedicord
Gregory F Hollis
Helen E Godonis
Ira B Dicker
Jeffrey T Billheimer
P304
P356
10.1182/BLOOD.V99.10.3540
P407
P577
2002-05-01T00:00:00Z